Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player


Sava in News

6th AUG 2013:-
(GMP) Approval from Ukrainian State Administration on Medicinal Products (SAUMP) Ukraine,

SAVA Healthcare Limited today announced that its manufacturing unit in Surendranagar near Ahmedabad,Gujarat has received Good Manufacturing Practices (GMP) approval from Ukrainian State Administration on Medicinal Products (SAUMP) Ukraine, a PIC/S member regulatory authority of global standards.

This GMP approval now certifies SAVA as one-of-the-few formulations manufacturing companies from India with PIC/S approval status.

PIC/S is a conjoint of Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme that promotes an active and constructive co-operation in the field of GMP (Good Manufacturing Practice) among the participating member countries by fostering international GMP harmonisation.

PIC/S also brings about single window export facilitation with provision to reduce duplication of inspections and enhance market access of the medicinal products amongst all member nations cost effectively.This saves times and cost for drug approval procedures and brings in high standard,uniform acceptable quality standard medicines that can be permitted into all member countries.

As of today, PIC/S brings about uniform licensing decisions among distinct 42 member countries which includes few of most regulated nations such as USA, Canada, UK,European Union, Australia, New Zealand, South Africa etc and partners with WHO Geneva, UNICEF and similar authorities.

The certification for SAVA was granted by Ukrainian state Administration on Medicinal Products (SAUMP) after its comprehensive audit of the GMP standards and Quality system of the manufacturing facility . The audit committee had commissioned an exhaustive audit involving 2-rounds of visit and detail investigation before imparting with this meritorious accreditation.

This manufacturing facility caters to the manufacture of general tablets, Capsules, ointment/creams, oral liquids, oral dry powders and Nasal Sprays . More than 300 products from these categories are marketed globally by SAVA and its channel partners .

Commenting on the development, Mr Vinod Jadhav, Chairman of the SAVA group stated ''This certification is a recognition for SAVA's High Quality standard manufacturing facilities , which are at par with international benchmarks set by PIC/S member nations . This accreditation further corroborates SAVA's commitment to most stringent Quality practices to safeguard public safety and also invigorates our vision to be a leading player in global manufacturing of the medicinal products'.

With this approval, SAVA expects to commence its supply of high quality products in Ukraine, Malaysia, Singapore and many other countries of its strategic interest immediately.


9th OCT 2012:- SAVA participated in CPHI, 2012

SAVA, yet again exhibited the grand show in this year's CPHI exhibition held at Spanish city-Madrid. This is world's biggest annual gathering of Pharma fraternity; throwing opportunity to showcase, interact & thought exchange for mutual benefits. The response was unprecedented with over 9,000 attendees from 133 countries around the globe during the 72 hours of exhibition. SAVA group is a multi-domain large integrated business group with its distinct verticals in Human life, Animal health and Herbals.

SAVA Nasal spray and Dry powder inhaler were the icons of SAVA booth this time around. SAVA forayed into global animal health business with newly formed entity SAVAVET. This would be the extended arm of SAVA to cater scorching pet care category. Savesta Herbals, also a distinct herbal manufacturing and research arm of SAVA was uniquely portrayed.

SAVA participated in CPHI, 2012 SAVA participated in CPHI, 2012 SAVA participated in CPHI, 2012


12th Oct 2012 Sava flags its Turkmenistan subsidiary

SAVA, the global pharmaceutical conglomerate entered in to the CIS market with the newly formed entity SAVA BioPharm Ltd.(a wholly owned subsidiary of SAVA HEALTHCARE Ltd.) by launching products in the Turkmenistan, mid of August this year. This is the latest destination to the existing geographic reach of Africa, Asia, Latin America & USA for the company's products rendered in Human Life & Consumer care. This has paved the way for company to penetrate in to these emerging semi-regulated markets with its widest range of therapeutic products.

The announcement went public on 16th August, ahead of the 'Annual Health Expo, 2012'. The launching ceremony held at the Hotel President in the capital of 'Ashgabat'. Around 100 eminent physicians attended the meet, during which they first time encountered applications of intranasal route of medication towards diseases like Diabetes insipidus, Osteoporosis and Allergic rhinitis. Sava is the first company to introduce intranasal spray products under the brands- Desonap, Citonap, Flutinap, and Momenap in this region.

Dr. Iuliya – one of the leading physicians from Ashgabat endorsed the product range after the product s briefing from top company executives, which was immensely appreciated by the medical fraternity. The overwhelming initial responses to these products were quite evident with visits of 500 physicians & pharmacists during the exhibition followed the launch. SAVA HEALTHCARE relishes the global distribution network covering 40 countries and strategic relationships with some of the world's leading pharmaceutical companies present in both developed and emerging markets in its global supply chain. SAVA HEALTHCARE has its flagship manufacturing facility located in Surendranagar, Gujarat (India) which specializes in Nasal Drug Delivery technology amongst many others . Manufacturing is ably supported by a 350 workforce and has strong Formulation development scientific pool. The company has 326 product registrations in over 30 markets globally.

6th Sept 2012 (SAVA HEALTHCARE Contract Manufacturing Facility Gets European GMP Approval)

SAVA HEALTHCARE Limited announced that one of its contract manufacturing facility located at SP-918, PHASE-III, RIICO Industrial area in Bhiwadi, Alwar district of Rajasthan, India has received European GMP (EU-GMP) approval from Czech republic for its manufacture of aseptically prepared small volume liquid finished formulations including eye drops. Read More

The Hindu: 31st October 2011 (Avesthagen floats JV with Sava HEALTHCARE to sell nutraceuticals)

BANGALORE: Biotech major Avesthagen has partnered with SAVA HEALTHCARE LTD of Pune to float 50:50 joint venture subsidiary — Dhanvantari Botanicals — to market a range of nutraceuticals products in the US and BRIS (Brazil, Russia, India, and South Africa) countries. Through this joint venture, Avesthagen grants and Sava HEALTHCARE earns marketing rights for Avesthagen's seven over-the-counter (OTC)-formulated tablet (including child-convenient dose such as fast-dissolving tablet), capsule and liquid forms for medical use. Dr Viloo Morawala-Patell, founder and CMD of Avesthagen Ltd, said, "The company so far has achieved convergence between food, pharma and population genetics. This transaction is part of our strategy to bring proprietary products, diagnostics, functional foods, and biological therapeutics focusing on metabolic disorders, cancer and neuro-degenerative disorders to consumers through partnerships." "Under the terms of the deal, Avesthagen will receive upfront payments and a 15 per cent royalty on product net sales in the US and BRIS countries," she added. Dhanvantari Botanical's products basket includes 11 OTC brands positioned for the wellness and nutraceutical markets. They are AmlaPure, Ashwagandha, BosWell, Gymnema, ThinkWell, Tribulus, Triphala, TriplaLax, WinterWell, XanoMax, and GojiMax and few qualified bulk ingredients.

Mr Vinod Jadhav, founder and Managing Director of Sava HEALTHCARE, commenting on the deal said: "We at Sava HEALTHCARE look forward to this strategic partnership to promote wellness and nutrition products in BRIS and the US. "With our strong sales and marketing force, and vital manufacturing and research capabilities in-built in our geosystem, we are now well-positioned to capture a significant share of the global healthcare market with such definitive value-added products."


16th April 2011 (Sava Healthcare signs agreement to be a part of JB SEZ):


15th March 2011 (Economic Times, Ahemadabad Edition):


Sava HEALTHCARE to Set Up Unit in JB SEZ

AHEMEDABAD: Sava HEALTHCARE has signed a deal with JB SEZ, the pharma specific SEZ from the JB Mody group and HBS Realtors, to set up a manufacturing plant. The plant, which is a part of Sava's expansion plans, will cater to it's exports to North America, Russia and CIS countries. Currently, the company exports to more than 20 countries in Asia, Africa , Latin America add CIS. Offered on a sub-lease, the size of the land is roughly 10 acres. The plant will cater to about 60% of the company's turnover. Spread across 312 acres at Panoli, the JB SEZ offers small, medium and large parcels of land to various pharma companies.



facebook twitter linkedin Youtube + SAVA Global